OncoMatch/Clinical Trials/NCT05199311
Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in Transplant Eligible Multiple Myeloma
Is NCT05199311 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies multiple treatments including Carfilzomib and Iberdomide for multiple myeloma.
Treatment: Carfilzomib · Iberdomide · Oral Dexamethasone — This is a multi-institution, open label, phase I/II study of Iberdomide, Carfilzomib, and dexamethasone (KID) in patients with newly diagnosed transplant eligible MM.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Other
Cancer type
Multiple Myeloma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: iberdomide (iberdomide)
Prior use of iberdomide
Cannot have received: systemic myeloma drug therapy
Exception: within the last 14 days of initiating IP
Use of any systemic myeloma drug therapy within the last 14 days of initiating IP
Cannot have received: investigational agent
Exception: within 28 days or 5 half-lives (whichever is longer) of initiating IP
Subject has been treated with an investigational agent (ie, an agent not commercially available) within 28 days or 5 half-lives (whichever is longer) of initiating IP
Lab requirements
Blood counts
ANC < 1,000/μL; Platelet count < 50,000/μL [excluded]
Kidney function
serious renal impairment (CrCl < 30 mL/min) or requiring dialysis [excluded]
Liver function
SGOT/AST or SGPT/ALT ≥ 2.5 x ULN; serum total bilirubin, direct bilirubin, or alkaline phosphatase ≥ 1.5 x ULN [excluded]
Cardiac function
LVEF < 40% by ECHO [excluded]; active congestive heart failure (NYHA III-IV), symptomatic ischemia, uncontrolled arrhythmias, QTc > 470 msec, pericardial disease, or MI within 4 months prior to randomization [excluded]
ANC < 1,000/μL; Platelet count < 50,000/μL; Corrected serum calcium > 13.5 mg/dL; SGOT/AST or SGPT/ALT ≥ 2.5 x ULN; serum total bilirubin, direct bilirubin, or alkaline phosphatase ≥ 1.5 x ULN; CrCl < 30 mL/min or requiring dialysis; LVEF < 40% by ECHO
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Lombardi Comprehensive Cancer Center · Washington D.C., District of Columbia
- John Theurer Cancer Center · Hackensack, New Jersey
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05199311 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior iberdomide, systemic myeloma drug therapy, investigational agent disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages